AdeTherapeutics, Inc.: Health Canada Approves Clinical Trial for Adhesion Prevention

SASKATOON, Saskatchewan--(BUSINESS WIRE)-- AdeTherapeutics, Inc. received Health Canada approval in November to conduct a double-blind randomized placebo controlled study in 30 patients to test its therapeutic to reduce adhesion (scar tissue) formation following laparoscopic procedure to remove an ectopic pregnancy.

Designed by surgeons, the trial is powered to potentially establish standard of care. The novel mechanism, which modulates normal healing process, is also being studied in other surgical areas of high unmet medical need.

The trial will be conducted at teaching hospitals in Canada with first patient enrolment expected in December 2011.

According to the Royal College of Obstetrics & Gynecology Journal Special Report on Adhesions, post-surgical scarring occurs in 93% of surgeries causing serious complications and costly re-admissions. United States National Institute for Heatlh (NIH) reported that only 1 in 3 women suffering an ectopic are able to have a baby.

The therapeutic is safe and easy to use for surgeons. The drug delivery system includes a common catheter attached to a Luer-Lock adapter. The drug is drawn up in a syringe and attached to the Luer-Lock adapter. At the end of the procedure, the catheter is thread down the trocar and the drug is evenly distributed to the surgical site.

AdeTherapeutics announced today a strategic partnership and collaboration with Numoda Corporation and Numoda Capital Innovations out of Philadelphia, PA, USA. Numoda will be responsible for helping AdeTherapeutics move its extensive portfolio of assets through clinical development, preparing it for regulatory approval and partnering.

“Numoda’s experience, resources and systems in executing dependable clinical trials eliminates many of the execution risks, adds value to our products and provides a robust data package for potential partners,” said Sanj Singh, AdeTherapeutics’ CEO.

“Our Company prides itself in helping promising scientific advances get to market, faster. AdeTherapeutics’ work is a prime example. And we have great confidence in this partnership,” said Mary Schaheen, Chairman, Numoda.

"This latest partnership is very encouraging. A member of the national industry association, talented companies such as AdeTherapeutics are nimble in their approach and able to capitalize on the opportunities which abound,” added Peter Brenders, President and CEO BIOTECanada.

About AdeTherapeutics, Inc.

AdeTherapeutics is a privately held market driven clinical-stage product development Company. The Company’s vision is to be the worldwide leader in developing products that deal with complications related to surgery. Designed by surgeons for surgeons and their patients. Portfolio of patented assets are well positioned to establish standard of care in large unmet medical need in surgery.

About Numoda Corporation

Numoda Corporation is a leading provider of clinical trial information and logistics services to promising life sciences companies. Numoda's services strengthen the business case for new therapies by ensuring efficient deployment of funds and immediate reporting for early assessment of progress to improve conditions for the acquisition of funding, licensing and partnering money for future success. The business offerings include business evaluation, budget projections and oversight, in conjunction with comprehensive management of clinical trials, patented information systems, logistics management and reporting tools with early transparency.



CONTACT:

AdeTherapeutics Inc.
Sanj Singh
CEO
Tel: 306-261-5189
[email protected]

KEYWORDS:   North America  Canada

INDUSTRY KEYWORDS:   Women  Surgery  Health  Clinical Trials  Pharmaceutical  Baby/Maternity  Parenting  Research  Consumer  Family  Science  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

The FDA rejected CytoDyn’s application for its lead program, a treatment for HIV because it’s missing some information.

Dewpoint Therapeutics is teaming up with Merck to develop a new way to fight HIV using its molecular condensates platform.

The study linked SPK-8011 to improvements in factor VIII expression and bleeding out to 3.3 years, but it will be 2021 before phase 3 dosing begins.